Conclusion

In HIV patients like in people with and without CVD [42], both anaerobic and aero­bic training induce some health benefits and improve physical fitness at different levels of body functions (Table 2), but the prescription and supervision of resistance training remain a medical task based on some limitations (Table 3).

Table 2 Physiological and biochemical effects of aerobic exercise (endurance) and anaerobic exercise (resistance training).

Table 3 Clinical conditions totally or partially contraindicating aerobic and resistance exercise

References

1.

2. Dube MP, Sattler FR (1998) Metabolic complica­tions of antiretroviral therapies. AIDS Clinical Care 10:41-44

3. Sullivan AK, Nelson MR (1997) Marked hyper- lipidaemia on ritonavir. AIDS 11:938-939

4. Hengel RL, Watts NB, Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350:1596

5. Miller KD, Jones E, Yanovski JA et al (1998) Vis­ceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871-875

6. Carr A, Samaras K, Burton S et al (1998) A syn­drome of peripheral lipodystrophy, hyperlipi- daemia and insulin resistance in patients receiv­ing HIV protease inhibitors. AIDS 12:F51-F58

7. Lo JC, Mulligan K, Tai VW et al (1998) “Buffalo hump” in men with HIV-infection. Lancet 351:867-870

8. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor- associated peripheral liopdystrophy, hyperlipi­demia, and insulin resistance. Lancet 352:1881-1883

9. Rosenberg HE, Mulder J, Sepkowitz K et al (1998) “Protease-paunch” in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. Fifth Con­ference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract 408

10. Kotler DP, Rosenbaum KB, Wang J et al (1998) Alterations in body fat distribution in HIV- infected men and women. Twelfth World AIDS Conference, Geneva, Switzerland, June-July 1998, abstract 32173

11. Engelson ES, Kotler DP, Tan YX et al (1998) Altered body fat distribution in HIV infection: regional body composition measurements by whole body MRI and DXA scans. Twelfth World AIDS Conference, Geneva, Switzerland, June-July 1998, abstract 32181

12. Boyle BA (1999) Lipodystrophy: A new phenom­enon? AIDS Reader 9:15-17

13. Gervasoni C, Ridolfo AL, Trifiro G et al (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

14. Bernasconi E (1999) Metabolic effects of pro­tease inhibitor therapy. AIDS Reader 9:254-269

15. Grinspoon S, Carr A(2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48-62

16. Mangili A, Murman DH, Zampini AM, Wanke CA (2006) Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from nutrition for healthy living cohort. Clin Infect Dis 42:836-842

17. Morse CG, Kovacs JA (2006) Metabolic and skeletal complications of HIV infection: the price of success. JAMA 296:844-854

18. Authier FJ, Chariot P, Gherardi RK (2005) Skeletal muscle involvement in human immun­odeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 32:247-260

19. Scott WB, Oursler KK, Katzel LI et al (2007)

Central activation, muscle performance, and physical function in men infected with human immunodeficiency virus. Muscle Nerve 36(3) (published online: 6 June 2007).

doi:10.1002/mus.20832

20. Scevola D, Di Matteo A, Giglio O, Uberti F (2006) HIV Infection-related cachexia and lipodystrophy In: Mantovani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 407-428

21. Scevola D, Di Matteo A, Uberti F et al (2000) Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Reader 10:365-375

22. Henry K, Zackin R, Dube M et al (2001) Meta­bolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably sup­pressed on an indinavir-containing regimen(ACTG 372A). Program and abstracts of the 8th Conference on Retroviruses and Oppor­tunistic Infections, Chicago, ILL, 4-8 February 2001, abstract 656

23. Adams PF, Marano MA (1995) Current esti­mates from the National Health Interview Sur­vey, 1994, National Center for Health Statistics. Vital Health Stat 10:193

24. Anonymous (1999) Healthy people 2010: draft for public comment. Department of Health and Human Services, Washington, DC

25.

26. Grunfeld C, Feingold KR (1992) Metabolic dis­turbances and wasting in the acquired immun­odeficiency syndrome. N Engl J Med 5:329-337

27. Lonergan JT, Havlir D, Barber E, Mathews WC (2001) Incidence and outcome of hyperlac- tatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-contain- ing regimens. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 4-8 February 200,1 abstract 624

28. Scevola D, Bottari G, Oberto L, Faggi A (1996) AIDS cachexia: basics and treatment. In: Ruf B, Pohle HD, Goebel FD, L’age M (eds) HIV-Infek- tion, Pathogenese, Diagnostik und Therapie. Socio-medico Verlag, Wessobrunn, Germany, pp 281-327

29. Oursler KK, Sorkin JD, Smith B, Katzel LI (2006) Reduced aerobic capacity and physical functioning in older HIV-infected men. AIDS Res Hum Retroviruses 22:1113-1121

30. Watson RR (ed) (2004) AIDS and heart disease. Informa Healthcare, London, 496 pp

31. Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in sta­ble, malnourished HIV-infected patients. Am J Clin Nutr 53:437-441

32. Grunfeld C, Pang M, Shimizu L et al (1992) Rest­ing energy expenditure, caloric intake and short-term weight change in human immunode­ficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 55:455-460

33. Shevitz AH (2000) Resting energy expenditure in the HAART era. AIDS Reader 10:539-544

34. WHO (1986) Working group on the use and interpretation of anthropometric indicators of nutritional status. Bull WHO 64:929-941

35. Kotler DP, Rosenbaum K, Wang J, Pearson RN (1999) Studies of body composition and fat dis­tribution in HIV-infected and control subjects.

36. Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scien- tifiche, Pavia, Italy

37. Scevola D, Giglio O, Scevola S(2006) Treatment of AIDS anorexia-cachexia syndrome and lipodystrophy. Mantovani G (ed) In: Cachexia and wasting: a modern approach. Springer, Milan, pp 429-456

38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497

39. Scevola D, Di Matteo A, Lanzarini P et al (2003) Effect of exercise and strength training on car­diovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17(S1):S123-S129

40. Volberding PA, Murphy RL, Barbaro G et al (2003) The Pavia consensus statement. AIDS 17(S1):S170-S179

41. Dube MP, Stein JH, Aberg JA et al (2003) Guide­lines for the evaluation and management of dys­lipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS clinical trials group. Clin Inf Dis 37:613-627

42. Williams MA, Haskell WL, Ades PA et al (2007) Resistance exercise in individuals with and without cardiovascular disease: 2007 update. A scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116:572. doi:10.1161/CIRCULATIONAHA.107.185214

43. Pollock ML,Vincent KR (1996) Resistance train­ing for health. In: The President’s Council on Physical Fitness and Sports Research Digest, series 2, no. 8

44. Smit E, Crespo CJ, Semba RD et al (2006) Phys­ical activity in a cohort of HIV-positive and HIV­negative injection drug users.

45. American College of Sports Medicine(2006) ACSM’s guidelines for exercise testing and pre­scription, 7th edn., Lippincott, Baltimore, MD

46. Brochu M, Savage P, Lee M et al (2002) Effects of resistance training on physical function in older disable women with coronary heart dis­ease. J Appl Physiol 92:672-678

47. Brown SP, Miller WC, Eason JM Exercise (2006) Physiology: basis of human movement in health and disease. Lippincott, Baltimore, MD, pp 98-124

48. Ibanez J, Izquierdo M, Arguelles I et al (2005) Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28:662-667

49. Sax PE (2006) Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 18:149-157

50. Scevola D, Di Matteo A, Giglio O, Uberti F (2007) Starvation: social, voluntary, and involun­tary causes of weight loss. In: Mantovani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 149-160

51. Scevola D, DiMatteo A, Giglio O, Scevola S (2006) Nutritional status assessment. In: Manto- vani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 93-110

52. Barrios A, Blanco F, Garcia-Benayas T et al (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16:2079-2081

53. Von Roenn JH (1994) Management of HIV-relat­ed body weight loss. Drugs 47:774-783

54. Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficit nutrizionali nell’AIDS. Clin Dietol 19:127-140

55. Tisdale M, Beck SA (1991) Inhibition of tumour induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103-107

56. Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657-2662

57. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci Terapia 3:77-83

58. Scevola D, Parazzini F, Negri C, Moroni M (1995) Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the Italian multicentre study. Fourth Congress of the European Association for Palliative Care, Barcelona, 6-9 December 1995, abstracts book, pp 443-447

59. Scevola D, Bottari G, Oberto L et al (1995) A double-blind-placebo controlled trial of mege- strol acetate on caloric intake and nutritional status in AIDS cachexia. Fourth Congress of European Association for Palliative Care, Barcelona, 6-9 December 1995, abstracts book, pp 427-437

60. Rondanelli M, Solerte SB, Fioravanti M et al (1997) Circadian secretory pattern of growth hormone, insulin-like growth factor type I, corti­sol, adrenocorticotropic hormone, thyroid-stim­ulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 14:1243-1249

61. Scevola D, Bottari G, Oberto L et al (1995) Megestrol acetate (MA) and growth hormone (rHGH) as combined therapy for AIDS cachexia. Fourth Congress of European Association for Palliative Care, Barcelona, 6-9 December 1995, abstracts book, pp 438-442

62. Wanke C, Gerrior J, Kantaros J et al (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099-2103

63. Saint-Marc T, Touraine JL (1999) Effects of met­formin on insulin resistance and central adipos­ity in patients receiving effective protease inhibitor (PI). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 672

64. Walli RK, Michl GM, Bogner JR et al (1999) Effects of the PPAR-Activator troglitazone on protease inhibitor associated peripheral insulin resistance. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 673

65. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D et al (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429-38

66. Torres R, Unger K (1999) The effect of recombi­nant human growth hormone on protease­inhibitor- associated fat maldistribution syn­drome. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 675

67. Strawford A, Barbieri T, Parks E et al (1999) Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV- related weight loss. JAMA 281:1282-1290

68. Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e Malattie Infettive. Abstracts Book XII Congresso Nazionale ADI. Torino, Italy, 16-18 November 1995, p 187

69. Scevola D, Bottari G, Oberto L et al (1996) Prob- lemi nutrizionali del paziente AIDS e strategie terapeutiche. Quad Cure Palliat (S1):51-64

70. Lauretani F, Russo CR, Bandinelli S et al (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagno­sis of sarcopenia. J Appl Physiol 95:1851-1860

71. Amsterdam EA (1997) Exercise in cardiovascu­lar health and disease. Yorke, New York

72. Smith BA, Neidig JL, Nickel JT et al (2001) Aer­obic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15:693-701

73. Montoye HJ (1975) Physical activity and health: an epidemiologic study of an entire community. Prentice-Hall, Englewood Cliffs, NJ

74. Katch FI, Freedson PS, Jones CA et al (1985) Evaluation of acute cardiorespiratory responses to hydraulic resistance exercise. Med Sci Sports Exerc 17:168-173

75. Crow RS, Rantahargiu PM, Prineas RJ et al (1986) Risk factors, exercise fitness and electro­cardiographic response to exercise in 12,866 men at risk of symptomatic coronary heart dis­ease. Am J Cardiol 57:1075-1082

76. Pollock M, Gaesser G, Butcher J et al (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespirato­ry and muscular fitness and flexibility in healthy adults. Med Sci Sports Exerc 30:975-991

77. Stringer WW, Berezovskaya M, O’Brien WA et al (1998) The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci Sports Exerc 30:11-16

78. Beniamini Y, Rubenstein JJ, Faigenbaum AD et al (1999) High-intensity strength training of patients enrolled in an outpatient cardiac reha­bilitation program. J Cardiopulm Rehabil 19:8-17

79. Braith RW, Stewart KJ (2006) Resistance exer­cise training: its role in the prevention of cardio­vascular disease. Circulation 113:2642-2650

80. McCartney N, McKelvie RS, Haslam DR, Jones NL (1991) Usefulness of weightlifting training in improving strength and maximal power out­put in coronary artery disease Am J Cardiol 67:939-945

81. Maeda S, Miyauchi T, Iemitsu M et al (2004) Resistance exercise training reduces plasma endothelin-1 concentration in healthy young humans. J Cardiovasc Pharmacol 44(suppl1): S443-S446

82. Stewart KJ, Bacher AC, Turner K et al (2005) Exercise and risk factors associated with meta­bolic syndrome in older adults. Am J Prev Med 28:9-18

83. Swain DP, Franklin BA (2006) Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise. Am J Car­diol 97:141-147

84. Vincent KR,Vincent HK, Braith RW et al (2002) Resistance exercise training attenuates exer­cise-induced lipid peroxidation in the elderly. Eur J Appl Physiol 87:416-423